CharlesFEisenbeisMDPhD

PubMed

• 6 citations
  Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
  Cynthia Osborne, Jagathi D. Challagalla, Charles F. Eisenbeis, Frankie A. Holmes, Marcus A. Neubauer, Nicholas Koutrelakos, Carlos A. Taboada, Sasha Vukelja, Sharon Wi...> ;Clinical Breast Cancer. 2017 Jul 10
• 72 citations
  A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
  Khuda D. Khan, Christos Emmanouilides, Don M. Benson, Deborah Hurst, Pablo Garcia, Glenn C. Michelson, Sandra Milan, Amy K. Ferketich, Lawrence D. Piro, John P. Leonar...> ;Clinical Cancer Research. 2006 Dec 1
• 87 citations
  Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
  Andrew P. Mone, Carolyn Cheney, Amy Banks, Susheela Tridandapani, Najma Mehter, Sara K. Guster, T. S. Lin, Charles F. Eisenbeis, Donn C. Young, John C. Byrd> ;Leukemia. 2006 Feb 1
• 18 citations
  Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by In...
  Charles F. Eisenbeis, Gregory B. Lesinski, Mirela Anghelina, Robin Parihar, Daniel Valentino, Jing Liu, Padma Nadella, Poongothai Sundaram, Donn C. Young, Mario Sznol,...> ;Journal of Clinical Oncology. 2005 Dec 1
• 38 citations
  Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia
  Andrew P. Mone, Shannon Puhalla, Susan P. Whitman, Robert A. Baiocchi, Julio Cruz, Tamara Vukosavljevic, Amy Banks, Charles F. Eisenbeis, John C. Byrd, Michael A. Cali...> ;Blood. 2005 Nov 15
• 28 citations
  IFN-γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice
  Julie Dierksheide, Robert A. Baiocchi, Amy K. Ferketich, Sameek Roychowdhury, Ronald P. Pelletier, Charles F. Eisenbeis, Michael A. Caligiuri, Anne M. VanBuskirk> ;Blood. 2005 Feb 15
• 26 citations
  Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder
  Sameek Roychowdhury, Robert A. Baiocchi, Srinivas Vourganti, Darshna Bhatt, Bradley W. Blaser, Aharon G. Freud, Jason Chou, Chang Shi Chen, Jim J. Xiao, Mark R. Parthu...> ;Journal of the National Cancer Institute. 2004 Oct 6
• 60 citations
  Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2: A Preclinical and Phase I Study
  Charles F. Eisenbeis, Andrew Grainger, Beth Fischer, Robert A. Baiocchi, Lester Carrodeguas, Sameek Roychowdhury, Lei Chen, Amy Banks, Thomas P. Davis, Donn C. Young, ...> ;Clinical Cancer Research. 2004 Sep 15
• Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in ritu...
  Eisenbeis CF, Leonard J, Rosenblatt J, Khan KD, Porcu P, Milan S, Wilson SE, Hurst D, Caligiuri MA, Piro L> ;J. Clin. Oncol.. 2004-07-15
• 20 citations
  Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma?
  Charles F. Eisenbeis, Michael A. Caligiuri, John C. Byrd> ;Clinical Cancer Research. 2003 Dec 1
• 61 citations
  Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma
  Sameek Roychowdhury, Ruoqi Peng, Robert A. Baiocchi, Darshna Bhatt, Srinivas Vourganti, John C. Grecula, Nilendu Gupta, Charles F. Eisenbeis, Gerard J. Nuovo, Weilian ...> ;Cancer Research. 2003 Mar 1
• 44 citations
  Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration.
  Pierluigi Porcu, Charles F. Eisenbeis, Ronald P. Pelletier, Elizabeth A. Davies, Robert A. Baiocchi, Sameek Roychowdhury, Srinivas Vourganti, Gerard J. Nuovo, William ...> ;Blood. 2002 Oct 1
• 40 citations
  GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder
  Robert A. Baiocchi, Jacqueline S. Ward, Lester Carrodeguas, Charles F. Eisenbeis, Ruoqi Peng, Sameek Roychowdhury, Srinivas Vourganti, Taryn Sekula, Maggie O’Brien, Me...> ;The Journal of Clinical Investigation. 2001 Sep 15
• 204 citations
  Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1.
  Abraham L. Brass, E Kehrli, C F Eisenbeis, Ursula Storb, Harinder Singh> ;Genes & Development. 1996 Sep 15
• 386 citations
  Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.
  Charles F. Eisenbeis, Harinder Singh, Ursula Storb> ;Genes & Development. 1995 Jun 1
• A case of pulmonary toxicity associated with G-CSF and doxorubicin administration.
  Eisenbeis, C. F., Winn, D., Poelman, S., Polsky, C. V., Rubenstein, J. H., Olopade, O. I.> ;Ann Hematol. 2001 Feb
• PU.1 is a component of a multiprotein complex which binds an essential site in the murine immunoglobulin lambda 2-4 enhancer.
  Eisenbeis, C. F., Singh, H., Storb, U.> ;Mol Cell Biol. 1993 Oct
• Join now to see all